[Clinical reevaluation of ofloxacin (OFLX) in urinary tract infections].
The clinical efficacy of the new quinolone antibacterial agent ofloxacin (OFLX) on urinary tract infections (UTI) was reevaluated. A 400-600 mg dose per day of OFLX was administered to 85 adult patients with various kinds of UTI. OFLX was effective clinically in 92.6% of the patients with acute UTI without urinary tract complications. In 81.8% of the patients with chronic complicated UTI because of organic or functional urinary tract disorders, OFLX was effective. This drug also has a marked bacteriological efficacy. No side effects or abnormal laboratory findings were seen in any of the patients administered OFLX.
Akiyama
T
T
Department of Urology, Kinki University School of Medicine.
Matsuura
T
T
Kurita
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D006801:Humans; D008875:Middle Aged; D015242:Ofloxacin; D010078:Oxazines / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D010078:Oxazines; D015242:Ofloxacin